PMC:7105881 / 21376-22151 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"702","span":{"begin":75,"end":86},"obj":"Species"},{"id":"703","span":{"begin":285,"end":295},"obj":"Species"}],"attributes":[{"id":"A702","pred":"tao:has_database_id","subj":"702","obj":"Tax:575864"},{"id":"A703","pred":"tao:has_database_id","subj":"703","obj":"Tax:11120"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Subunit vaccines are vaccines developed based on the synthetic peptides or recombinant proteins. Unlike inactivated or live-attenuated virus and some viral vectored vaccines, this vaccine type mainly contains specific viral antigenic fragments, but without including any components of infectious viruses, eliminating the concerns of incomplete inactivation, virulence recovery, or pre-existing immunity (Du et al., 2008; Deng et al., 2012). Similar to DNA or VLP-based vaccines, subunit vaccines are generally safe without causing potential harmful immune responses, making them promising vaccine candidates. Moreover, subunit vaccines may target specific, well-defined neutralizing epitopes with improved immunogenicity and/or efficacy (Du et al., 2008; Zhang et al., 2014)."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T88","span":{"begin":87,"end":95},"obj":"Body_part"},{"id":"T89","span":{"begin":452,"end":455},"obj":"Body_part"}],"attributes":[{"id":"A88","pred":"fma_id","subj":"T88","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A89","pred":"fma_id","subj":"T89","obj":"http://purl.org/sig/ont/fma/fma74412"}],"text":"Subunit vaccines are vaccines developed based on the synthetic peptides or recombinant proteins. Unlike inactivated or live-attenuated virus and some viral vectored vaccines, this vaccine type mainly contains specific viral antigenic fragments, but without including any components of infectious viruses, eliminating the concerns of incomplete inactivation, virulence recovery, or pre-existing immunity (Du et al., 2008; Deng et al., 2012). Similar to DNA or VLP-based vaccines, subunit vaccines are generally safe without causing potential harmful immune responses, making them promising vaccine candidates. Moreover, subunit vaccines may target specific, well-defined neutralizing epitopes with improved immunogenicity and/or efficacy (Du et al., 2008; Zhang et al., 2014)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T84","span":{"begin":285,"end":295},"obj":"Disease"}],"attributes":[{"id":"A84","pred":"mondo_id","subj":"T84","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"Subunit vaccines are vaccines developed based on the synthetic peptides or recombinant proteins. Unlike inactivated or live-attenuated virus and some viral vectored vaccines, this vaccine type mainly contains specific viral antigenic fragments, but without including any components of infectious viruses, eliminating the concerns of incomplete inactivation, virulence recovery, or pre-existing immunity (Du et al., 2008; Deng et al., 2012). Similar to DNA or VLP-based vaccines, subunit vaccines are generally safe without causing potential harmful immune responses, making them promising vaccine candidates. Moreover, subunit vaccines may target specific, well-defined neutralizing epitopes with improved immunogenicity and/or efficacy (Du et al., 2008; Zhang et al., 2014)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T237","span":{"begin":63,"end":71},"obj":"http://purl.obolibrary.org/obo/PR_000018263"},{"id":"T238","span":{"begin":135,"end":140},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T239","span":{"begin":296,"end":303},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"}],"text":"Subunit vaccines are vaccines developed based on the synthetic peptides or recombinant proteins. Unlike inactivated or live-attenuated virus and some viral vectored vaccines, this vaccine type mainly contains specific viral antigenic fragments, but without including any components of infectious viruses, eliminating the concerns of incomplete inactivation, virulence recovery, or pre-existing immunity (Du et al., 2008; Deng et al., 2012). Similar to DNA or VLP-based vaccines, subunit vaccines are generally safe without causing potential harmful immune responses, making them promising vaccine candidates. Moreover, subunit vaccines may target specific, well-defined neutralizing epitopes with improved immunogenicity and/or efficacy (Du et al., 2008; Zhang et al., 2014)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T88","span":{"begin":63,"end":71},"obj":"Chemical"},{"id":"T89","span":{"begin":87,"end":95},"obj":"Chemical"},{"id":"T90","span":{"begin":452,"end":455},"obj":"Chemical"}],"attributes":[{"id":"A88","pred":"chebi_id","subj":"T88","obj":"http://purl.obolibrary.org/obo/CHEBI_16670"},{"id":"A89","pred":"chebi_id","subj":"T89","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A90","pred":"chebi_id","subj":"T90","obj":"http://purl.obolibrary.org/obo/CHEBI_16991"}],"text":"Subunit vaccines are vaccines developed based on the synthetic peptides or recombinant proteins. Unlike inactivated or live-attenuated virus and some viral vectored vaccines, this vaccine type mainly contains specific viral antigenic fragments, but without including any components of infectious viruses, eliminating the concerns of incomplete inactivation, virulence recovery, or pre-existing immunity (Du et al., 2008; Deng et al., 2012). Similar to DNA or VLP-based vaccines, subunit vaccines are generally safe without causing potential harmful immune responses, making them promising vaccine candidates. Moreover, subunit vaccines may target specific, well-defined neutralizing epitopes with improved immunogenicity and/or efficacy (Du et al., 2008; Zhang et al., 2014)."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T28","span":{"begin":358,"end":367},"obj":"http://purl.obolibrary.org/obo/GO_0016032"},{"id":"T29","span":{"begin":358,"end":367},"obj":"http://purl.obolibrary.org/obo/GO_0009405"},{"id":"T30","span":{"begin":549,"end":565},"obj":"http://purl.obolibrary.org/obo/GO_0006955"}],"text":"Subunit vaccines are vaccines developed based on the synthetic peptides or recombinant proteins. Unlike inactivated or live-attenuated virus and some viral vectored vaccines, this vaccine type mainly contains specific viral antigenic fragments, but without including any components of infectious viruses, eliminating the concerns of incomplete inactivation, virulence recovery, or pre-existing immunity (Du et al., 2008; Deng et al., 2012). Similar to DNA or VLP-based vaccines, subunit vaccines are generally safe without causing potential harmful immune responses, making them promising vaccine candidates. Moreover, subunit vaccines may target specific, well-defined neutralizing epitopes with improved immunogenicity and/or efficacy (Du et al., 2008; Zhang et al., 2014)."}

{"project":"2_test","denotations":[{"id":"32265848-18301805-36511085","span":{"begin":415,"end":419},"obj":"18301805"},{"id":"32265848-22684468-36511086","span":{"begin":434,"end":438},"obj":"22684468"},{"id":"32265848-18301805-36511087","span":{"begin":749,"end":753},"obj":"18301805"},{"id":"32265848-24766432-36511088","span":{"begin":769,"end":773},"obj":"24766432"}],"text":"Subunit vaccines are vaccines developed based on the synthetic peptides or recombinant proteins. Unlike inactivated or live-attenuated virus and some viral vectored vaccines, this vaccine type mainly contains specific viral antigenic fragments, but without including any components of infectious viruses, eliminating the concerns of incomplete inactivation, virulence recovery, or pre-existing immunity (Du et al., 2008; Deng et al., 2012). Similar to DNA or VLP-based vaccines, subunit vaccines are generally safe without causing potential harmful immune responses, making them promising vaccine candidates. Moreover, subunit vaccines may target specific, well-defined neutralizing epitopes with improved immunogenicity and/or efficacy (Du et al., 2008; Zhang et al., 2014)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T131","span":{"begin":0,"end":96},"obj":"Sentence"},{"id":"T132","span":{"begin":97,"end":440},"obj":"Sentence"},{"id":"T133","span":{"begin":441,"end":608},"obj":"Sentence"},{"id":"T134","span":{"begin":609,"end":775},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Subunit vaccines are vaccines developed based on the synthetic peptides or recombinant proteins. Unlike inactivated or live-attenuated virus and some viral vectored vaccines, this vaccine type mainly contains specific viral antigenic fragments, but without including any components of infectious viruses, eliminating the concerns of incomplete inactivation, virulence recovery, or pre-existing immunity (Du et al., 2008; Deng et al., 2012). Similar to DNA or VLP-based vaccines, subunit vaccines are generally safe without causing potential harmful immune responses, making them promising vaccine candidates. Moreover, subunit vaccines may target specific, well-defined neutralizing epitopes with improved immunogenicity and/or efficacy (Du et al., 2008; Zhang et al., 2014)."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T412","span":{"begin":135,"end":140},"obj":"NCBITaxon:10239"},{"id":"T413","span":{"begin":150,"end":155},"obj":"NCBITaxon:10239"},{"id":"T414","span":{"begin":156,"end":164},"obj":"SO:0000440"},{"id":"T415","span":{"begin":218,"end":223},"obj":"NCBITaxon:10239"},{"id":"T416","span":{"begin":224,"end":233},"obj":"CHEBI:59132;CHEBI:59132"},{"id":"T417","span":{"begin":296,"end":303},"obj":"NCBITaxon:10239"},{"id":"T418","span":{"begin":549,"end":555},"obj":"UBERON:0002405;GO:0006955"},{"id":"T419","span":{"begin":556,"end":565},"obj":"GO:0006955"},{"id":"T420","span":{"begin":683,"end":691},"obj":"BV_9"},{"id":"T421","span":{"begin":706,"end":720},"obj":"BV_15"},{"id":"T22303","span":{"begin":135,"end":140},"obj":"NCBITaxon:10239"},{"id":"T10835","span":{"begin":150,"end":155},"obj":"NCBITaxon:10239"},{"id":"T54276","span":{"begin":156,"end":164},"obj":"SO:0000440"},{"id":"T99025","span":{"begin":218,"end":223},"obj":"NCBITaxon:10239"},{"id":"T54831","span":{"begin":224,"end":233},"obj":"CHEBI:59132;CHEBI:59132"},{"id":"T20449","span":{"begin":296,"end":303},"obj":"NCBITaxon:10239"},{"id":"T15032","span":{"begin":549,"end":555},"obj":"UBERON:0002405;GO:0006955"},{"id":"T50118","span":{"begin":556,"end":565},"obj":"GO:0006955"},{"id":"T21274","span":{"begin":683,"end":691},"obj":"BV_9"},{"id":"T22530","span":{"begin":706,"end":720},"obj":"BV_15"}],"text":"Subunit vaccines are vaccines developed based on the synthetic peptides or recombinant proteins. Unlike inactivated or live-attenuated virus and some viral vectored vaccines, this vaccine type mainly contains specific viral antigenic fragments, but without including any components of infectious viruses, eliminating the concerns of incomplete inactivation, virulence recovery, or pre-existing immunity (Du et al., 2008; Deng et al., 2012). Similar to DNA or VLP-based vaccines, subunit vaccines are generally safe without causing potential harmful immune responses, making them promising vaccine candidates. Moreover, subunit vaccines may target specific, well-defined neutralizing epitopes with improved immunogenicity and/or efficacy (Du et al., 2008; Zhang et al., 2014)."}